Physician profile
Deepali Prasad
NPI 1962607952
$4,627.56
in general payments reported to CMS, 2019-2025
23 companies · $1,061 in 2025
The $1,061 reported for 2025 was more than what 79% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2021: $385 · 2022: $659 · 2023: $1,246 · 2024: $1,151 · 2025: $1,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,420 · Education: $38.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,420.26 |
| Education | $38.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,487.00 | 2021-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $637.15 | 2021-2025 | Veltassa, Korsuva |
| Amgen INC. | $511.85 | 2021-2025 | Krystexxa, Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $366.75 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $223.00 | 2023-2025 | Jardiance |
| Mallinckrodt Hospital Products INC. | $197.86 | 2022-2025 | Acthar |
| Fresenius USA Marketing, INC. | $152.05 | 2024-2025 | Velphoro, Velphoro |
| Glaxosmithkline, LLC. | $150.49 | 2022-2024 | Benlysta, Jesduvroq |
| Otsuka America Pharmaceutical, INC. | $149.18 | 2022-2025 | Jynarque |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $122.85 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $113.76 | 2022-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $68.42 | 2025 | Lupkynis |
| Abbott Laboratories | $63.08 | 2024 | Infinity, Xience Skypoint |
| Akebia Therapeutics INC | $57.03 | 2024 | Vafseo, Auryxia |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $46.78 | 2023-2025 | Crysvita |
| Renalytix Ai, INC. | $35.67 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Lilly USA, LLC | $30.36 | 2023-2024 | Jardiance |
| Idorsia Pharmaceuticals US INC | $22.36 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $19.99 | 2024 | Crysvita |
| Forte Bio-Pharma LLC | $17.80 | 2025 | Prolate, Nalocet, Tanlor |
| Horizon Therapeutics Plc | $14.79 | 2023 | Krystexxa |
| Fresenius USA Manufacturing, INC. | $14.34 | 2023 | Velphoro, Korsuva |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepali Prasad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.